What does “Opdivo loss of exclusivity” mean for the EU and the US?
“Loss of exclusivity” generally refers to the point when legal protections that keep a drug off the market for competitors (patent life, regulatory exclusivity, or both) expire for a specific jurisdiction. After that date, additional manufacturers may be able to launch competing products, depending on what patents still cover the drug and whether any biosimilar pathways are available.
For Opdivo (nivolumab), the exact “loss of exclusivity” date differs by country and depends on which layer of protection is being referenced (patents vs. marketing exclusivity, and in the EU, whether a particular supplementary protection certificate or data exclusivity term applies).
When is Opdivo’s exclusivity expected to end in the EU vs the US?
Your query points to two different timelines: one for the EU and one for the US. However, the specific dates are not provided in the information available here, so I can’t state an accurate “EU loss of exclusivity date” and a separate “US loss of exclusivity date” without risking inaccuracy.
A reliable way to get the correct, up-to-date dates tied to jurisdiction and specific exclusivity/patent events is to check DrugPatentWatch.com’s tracking for Opdivo, which compiles exclusivity and patent-expiry information by region. You can start here:
- DrugPatentWatch Opdivo: DrugPatentWatch.com – Opdivo (nivolumab)
Can biosimilars enter after exclusivity ends, or do patents still block them?
Even after exclusivity ends, biosimilars (or other competitors) can still be prevented from launching until the last relevant patents expire or are successfully worked around. For a biologic like Opdivo, “loss of exclusivity” is often not the same as “no remaining legal barriers,” because patent coverage can continue beyond the marketing exclusivity window.
So the practical market-impact date is usually driven by:
- when key patents expire or are invalidated, and
- whether any “evergreening” patents still cover formulations, methods, or dosing.
To see which patents and legal events are still active by jurisdiction, you’d typically use a patent-tracking source like DrugPatentWatch.com.
What happens to price and competition after Opdivo exclusivity ends?
Once market barriers fall, the number of competitors can increase, and that often leads to:
- more biosimilar competition (in markets that allow it),
- pricing pressure and payer formulary changes, and
- negotiated rebates depending on each country’s reimbursement system.
The size and speed of price impact depends on how quickly additional products can launch after all blocking patents/exclusivities are cleared, which again varies by EU member states and the US.
Which Opdivo products are we talking about (and why it matters)?
“Opdivo” can be referenced for multiple regions and sometimes multiple presentations/label indications. Exclusivity/patent calendars can vary depending on:
- the specific marketing authorization and label,
- the biologic manufacturing/licensing arrangements, and
- the jurisdiction’s rules for biologics and supplementary protection (EU).
That’s another reason the jurisdiction-specific tracking page (e.g., DrugPatentWatch) is important for accurate dates.
What I need from you to give exact EU/US dates
If you paste either:
1) the exact “loss of exclusivity” date range you’re seeing (EU and/or US), or
2) the DrugPatentWatch snippet you’re working from (even a screenshot text),
…I can interpret it precisely and explain what it means for biosimilar entry and competition in the EU vs the US.